Trial Profile

First-in-Human, Escalating Oral Dose Study of RGT-419B Given Alone and With Endocrine Therapy in Subjects With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced/Metastatic Breast Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 23 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RGT-419B (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
Focus Adverse reactions; First in man
Sponsors Regor Therapeutics

14 Nov 2024 Planned number of patients changed from 18 to 64.
26 Jul 2024 Planned End Date changed from 28 Aug 2024 to 30 Sep 2026.
26 Jul 2024 Planned primary completion date changed from 28 Feb 2024 to 30 Dec 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com